Linked Life Data

18832343

Source:http://linkedlifedata.com/resource/pubmed/id/18832343

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18832343rdf:typepubmed:Citationlld:pubmed
pubmed-article:18832343lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0679646lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0150097lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0003385lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0018810lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0388753lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0529351lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:18832343lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:18832343pubmed:issue4lld:pubmed
pubmed-article:18832343pubmed:dateCreated2008-12-17lld:pubmed
pubmed-article:18832343pubmed:abstractTextAntimuscarinics, used commonly to treat overactive bladder, may differ in their potential to increase heart rate via effects on cardiac muscarinic M2 receptors. This prospective, 3-way crossover, randomized, double-blind study assessed the heart rate effects of 7 days' exposure to a nonselective M2/M3 receptor blocker (tolterodine; 4 mg/d), a highly selective M3 receptor blocker (darifenacin; 15 mg/d), and placebo in 162 healthy participants > or = 50 years. Heart rate was measured by 24-hour Holter monitoring. Tolterodine significantly increased heart rate versus darifenacin and heart rate versus placebo, while darifenacin did not affect heart rate versus placebo. The proportion of participants with an increase in mean heart rate per 24 hours of > or =5 beats per minute was higher with tolterodine than with darifenacin (P = .0004) or with placebo (P = .0114) but did not differ between darifenacin and placebo. The results show that antimuscarinics exert differential effects on heart rate depending on their muscarinic receptor profile. This should be considered when selecting a treatment.lld:pubmed
pubmed-article:18832343pubmed:languageenglld:pubmed
pubmed-article:18832343pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:citationSubsetIMlld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18832343pubmed:statusMEDLINElld:pubmed
pubmed-article:18832343pubmed:monthDeclld:pubmed
pubmed-article:18832343pubmed:issn1074-2484lld:pubmed
pubmed-article:18832343pubmed:authorpubmed-author:OlshanskyBria...lld:pubmed
pubmed-article:18832343pubmed:authorpubmed-author:RekedaLudmyla...lld:pubmed
pubmed-article:18832343pubmed:authorpubmed-author:EbingerUrsula...lld:pubmed
pubmed-article:18832343pubmed:authorpubmed-author:ViegasAndreaAlld:pubmed
pubmed-article:18832343pubmed:authorpubmed-author:BrumJoséJlld:pubmed
pubmed-article:18832343pubmed:authorpubmed-author:EgermarkMathi...lld:pubmed
pubmed-article:18832343pubmed:issnTypePrintlld:pubmed
pubmed-article:18832343pubmed:volume13lld:pubmed
pubmed-article:18832343pubmed:ownerNLMlld:pubmed
pubmed-article:18832343pubmed:authorsCompleteYlld:pubmed
pubmed-article:18832343pubmed:pagination241-51lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:meshHeadingpubmed-meshheading:18832343...lld:pubmed
pubmed-article:18832343pubmed:year2008lld:pubmed
pubmed-article:18832343pubmed:articleTitleDifferential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.lld:pubmed
pubmed-article:18832343pubmed:affiliationUniversity of Iowa Hospitals, Iowa City, Iowa 52242, USA. brian-olshansky@uiowa.edulld:pubmed
pubmed-article:18832343pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18832343pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18832343pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18832343pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18832343lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18832343lld:pubmed